Dopexamine: Difference between revisions
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
No edit summary |
||
| Line 24: | Line 24: | ||
| routes_of_administration = | | routes_of_administration = | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | {{SI}} | ||
{{CMG}} | {{CMG}} | ||
==Overview== | |||
'''Dopexamine''' is a synthetic analogue of dopamine. Despite this, it is a [[Beta1-adrenergic agonist|β<sub>1</sub>]] and [[beta2-adrenergic receptor agonist|β<sub>2</sub>-adrenergic receptor agonist]].<ref name="PMID7902685">{{cite journal |author=Perrin G, Papazian L, Martin C. |title=Dopexamine: a new dopaminergic agonist |journal=Ann Fr Anesth Reanim. |volume=12 |issue=3 |pages=308–320 |year=1993 |month=|pmid=7902685 |pmc= |doi= |url=}}</ref> Its action at [[dopamine receptor]] D1 mediates relaxation of vascular smooth muscle in renal, mesenteric, cerebral and coronary arteries. Mild action at D2 receptors decreases noradrenaline release.<ref name="pmid2862944">{{cite journal |author=Brown RA, Dixon J, Farmer JB, ''et al.'' |title=Dopexamine: a novel agonist at peripheral dopamine receptors and beta 2-adrenoceptors |journal=Br. J. Pharmacol. |volume=85 |issue=3 |pages=599–608 |date=July 1985 |pmid=2862944 |pmc=1916510 |doi= 10.1111/j.1476-5381.1985.tb10554.x|url=}}</ref> | |||
Use in [[sepsis]] has been proposed.<ref name="pmid16893450">{{cite journal |author=Birnbaum J, Klotz E, Spies CD, ''et al.'' |title=Effects of dopexamine on the intestinal microvascular blood flow and leucocyte activation in a sepsis model in rats |journal=Crit Care |volume=10 |issue=4 |pages=R117 |year=2006 |pmid=16893450 |pmc=1750974 |doi=10.1186/cc5011 |url=http://ccforum.com/content/10/4/R117}}</ref> | |||
It is used as an [[inotropic]] agent in cardiac failure.<ref name="pmid12740229">{{cite journal |author=Lisbon A |title=Dopexamine, dobutamine, and dopamine increase splanchnic blood flow: what is the evidence? |journal=Chest |volume=123 |issue=5 Suppl |pages=460S–3S |date=May 2003 |pmid=12740229 |doi= 10.1378/chest.123.5_suppl.460S|url=http://www.chestjournal.org/cgi/pmidlookup?view=long&pmid=12740229}}</ref> Side effects include arrhythmia, tremor, angina and flushing. | |||
==References== | |||
{{reflist|2}} | |||
{{Cardiac stimulants excluding cardiac glycosides}} | |||
[[Category:Catecholamines]] | [[Category:Catecholamines]] | ||
[[Category: | [[Category:Dopamine agonists]] | ||
[[Category:Drugs]] | [[Category:Inotropic agents]] | ||
[[Category:Cardiovascular Drugs]] | |||
[[Category:Drug]] | |||
Latest revision as of 00:27, 24 July 2014
 | |
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C22H32N2O2 |
| Molar mass | 429.43 g/mol |
|
WikiDoc Resources for Dopexamine |
|
Articles |
|---|
|
Most recent articles on Dopexamine |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Dopexamine at Clinical Trials.gov Clinical Trials on Dopexamine at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Dopexamine
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Dopexamine Discussion groups on Dopexamine Patient Handouts on Dopexamine Directions to Hospitals Treating Dopexamine Risk calculators and risk factors for Dopexamine
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Dopexamine |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Dopexamine is a synthetic analogue of dopamine. Despite this, it is a β1 and β2-adrenergic receptor agonist.[1] Its action at dopamine receptor D1 mediates relaxation of vascular smooth muscle in renal, mesenteric, cerebral and coronary arteries. Mild action at D2 receptors decreases noradrenaline release.[2]
Use in sepsis has been proposed.[3]
It is used as an inotropic agent in cardiac failure.[4] Side effects include arrhythmia, tremor, angina and flushing.
References
- ↑ Perrin G, Papazian L, Martin C. (1993). "Dopexamine: a new dopaminergic agonist". Ann Fr Anesth Reanim. 12 (3): 308–320. PMID 7902685.
- ↑ Brown RA, Dixon J, Farmer JB; et al. (July 1985). "Dopexamine: a novel agonist at peripheral dopamine receptors and beta 2-adrenoceptors". Br. J. Pharmacol. 85 (3): 599–608. doi:10.1111/j.1476-5381.1985.tb10554.x. PMC 1916510. PMID 2862944.
- ↑ Birnbaum J, Klotz E, Spies CD; et al. (2006). "Effects of dopexamine on the intestinal microvascular blood flow and leucocyte activation in a sepsis model in rats". Crit Care. 10 (4): R117. doi:10.1186/cc5011. PMC 1750974. PMID 16893450.
- ↑ Lisbon A (May 2003). "Dopexamine, dobutamine, and dopamine increase splanchnic blood flow: what is the evidence?". Chest. 123 (5 Suppl): 460S–3S. doi:10.1378/chest.123.5_suppl.460S. PMID 12740229.
- Pages with script errors
- CS1 maint: Multiple names: authors list
- CS1 maint: Explicit use of et al.
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Catecholamines
- Dopamine agonists
- Inotropic agents
- Cardiovascular Drugs
- Drug